EUCTR2005-006201-12-IT进行中（未招募）1 期
A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK-0594 in Patients With Overactive Bladder - ND
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 530
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •a.Patient agrees to participate as indicated by signing the appropriate informed consent.
- •b.Patient is female, aged 40 to 74 years, inclusive, with a history of no menses for at least 1 year and demonstrates serum FSH level equal to or greater than the lower limit of normal for post-menopausal women.
- •Note: Up to 10% patients can be male patients 40 to 74 years of age, inclusive.
- •c.Patient is ambulatory, is in good general physical and mental health, and appears capable of understanding and completing the study procedures including proper completion of the voiding diary.
- •d.History (may be verbal per patient) of urinary urgency for at least 3 months prior to Visit 1. Urodynamic evaluation is NOT required.
- •Visit 2 Criteria
- •e.In the opinion of the investigator, the patient can adequately complete a diary, as assessed by a review of the diary completed during screening.
- •f.The average number of micturitions calculated from the screening diary is ≥8 per diary day.
- •g.The average number of urge incontinence from the screening diary is ≥1 per diary day.
- •h.The total number of urge incontinence episodes exceeds the total number of stress incontinence episodes on the screening diary.
- •Visit 3 Criteria
- •i.In the opinion of the investigator, the patient can adequately complete a diary, as assessed by a review of the completed run-in diary
- •j.The average number of micturitions calculated from the run-in diary is ≥8 per diary day.
- •k.The average number of urge incontinence episodes from the run-in diary is ≥1 per diary day.
- •l.The total number of urge incontinence episodes exceeds the total number of stress incontinence episodes on the run-in diary.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •General Medical
- •a.Evidence from clinical history of any illness or condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering MK-0594 to the patient, such as mental incompetence, multiple and/or severe allergies, and/or clinically unstable diseases of the cardiovascular, hepatic, renal, gastrointestinal, or hematologic systems that require further medical evaluation and/or treatment.
- •b.Evidence from current history of diabetes insipidus, uncontrolled hyperglycemia (fasting blood glucose >150 mg/dL, and/or non-fasting blood glucose >180 mg/dL) or uncontrolled hypercalcemia (blood total calcium >11 mg/dL).
- •c.A history of injury, surgery, or neurodegenerative diseases (e.g., multiple sclerosis) that could affect the lower urinary tract or its nerve supply.
- •d.A history of Lower Urinary Tract Symptoms (LUTS) or Benign Prostatic Hypertrophy (BPH).
- •e.A history of rectal incontinence.
- •f.A history of continual urine leakage or patient is unaware of urine leakage.
- •g.A history of surgery to correct stress urinary incontinence or prolapsed uterus within 6 months.
- •h.Bladder training or electrostimulation within 2 weeks prior to Visit 1 or plans to initiate during the study.
- •i.Active or recurrent (>6 episodes per year) urinary tract infections by clinical history, clinical symptoms, or laboratory criteria (≥5 WBC or ≥20 bacteria per high-powered field in a spun specimen and/or a positive urine culture defined as ≥105 colony forming units (CFU)/mL in 1 specimen).
- •j.Requirement for an indwelling catheter or intermittent catheterization.
- •Medications
- •k.Patient is not willing to discontinue any of the following therapies at least 3 weeks prior to Visit 2 and remain off the therapy for the duration of the study:
- •Anticholinergics including but not limited to oxybutynin, tolterodine, trospium, darafenacin, hyoscyamine, and propantheline.
- •Smooth muscle relaxants including but not limited to flavoxate, dicyclomine, propiverine.
- •l.Patient is receiving therapy with any of the following medications for less than 8 weeks prior to Visit 1 or plans to initiate or change therapy during the study.
- •Tricyclic antidepressants or combinations including but not limited to amitriptyline, imipramine, and doxepin.
- •Seretonin and/or norepinephrine reuptake inhibitors including but not limited to duloxetine.
- •Calcium channel blockers including but not limited to nimodipine and nifedipine.
- •Alpha-adrenergic agonists including but not limited to ephedrine and pseudoephedrine.
- •Diuretic therapy including but not limited to furosemide and hydrochlorothiazide.
- •m.Patient is receiving systemic or topical hormone replacement therapy including but not limited to estrogen and estrogen/progesterone combination products for less than 12 weeks prior to Visit 1 or plans to initiate or change therapy during the study.
- •n.Patient has used any medication with a narrow therapeutic window, including but not limited to warfarin (COUMADIN?, DuPont Pharma) and digoxin within 4 weeks prio
研究者
相似试验
进行中（未招募）
1 期
A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK-0594 in Patients With Overactive Bladder - MK-0594 Overactive Bladder Dose-Ranging StudyOveractive BladderEUCTR2005-005606-23-DKMerck & Co. Inc.530
进行中（未招募）
1 期
A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK-0594 in Patients With Overactive Bladder Estudio multicéntrico, doble ciego, aleatorizado, controlado con placebo y fármaco activo, en grupos paralelos y de dosificación del MK-0594 en pacientes con vejiga inestable - MK-0594 Overactive Bladder Dose-Ranging StudyOveractive BladderMedDRA version: 8.0 Level: LLT Classification code 10059617EUCTR2005-005606-23-ESMerck Sharp and Dohme de España530
进行中（未招募）
不适用
A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK-0594 in Patients With Overactive Bladder - MK-0594 Overactive Bladder Dose-Ranging StudyOveractive BladderMedDRA version: 8.0Level: LLTClassification code 10059617EUCTR2005-005606-23-SEMerck Sharp & Dohme (Sweden) AB530
进行中（未招募）
1 期
A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK-0594 in Patients With Overactive Bladder - MK-0594 Overactive Bladder Dose-Ranging StudyOveractive BladderEUCTR2005-005606-23-DEMerck &Co.Inc.530
进行中（未招募）
1 期
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433EUCTR2017-001225-41-FRAbbVie Deutschland GmbH & Co. KG738